Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
13
Stocks News & Analysis
stocks
The trillion-dollar club: Are these mega-sized stocks still buys?
stocks
New pricing model for embattled ASX tech leader
stocks
Chart of the Week: We see opportunity in Mineral Resources despite debt concerns
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,926.10 | 19.30 | 0.22% |
| CAC 40 | 8,154.90 | 32.87 | 0.40% |
| DAX 40 | 24,029.72 | 147.69 | 0.62% |
| Dow JONES (US) | 47,850.94 | 31.96 | -0.07% |
| FTSE 100 | 9,727.48 | 16.61 | 0.17% |
| HKSE | 26,085.08 | 149.18 | 0.58% |
| NASDAQ | 23,505.14 | 51.04 | 0.22% |
| Nikkei 225 | 50,491.87 | 536.55 | -1.05% |
| NZX 50 Index | 13,483.99 | 31.63 | -0.23% |
| S&P 500 | 6,857.12 | 7.40 | 0.11% |
| S&P/ASX 200 | 8,634.60 | 20.50 | 0.24% |
| SSE Composite Index | 3,902.81 | 27.01 | 0.70% |